Mirati - oncology?

Quote
MIrarti tunes begin to play... An ode to get the puma rejects out...

here we come, oh here we come

puma rejects, oh here we come

its not to late, oh its not too late

to resend that resignation, oh its not too late

puma wants you back, yes puma wants you back

come back home to the 2 dollar shit show shack...
 




anonymous said:
Deciphera

same thing. Stock now at 35. Owners sold all their stock at 58. They knew they were going to tank.

I worked under Meeks at ipsen. He’s incompetent and add arrogant. If you are a loser and asshole the future is inevitably going to stink
Click to expand...

update - DCPH has been below $10 since end of November. Slashed headcount and into the slow cash bleed of death now. One trick ponies fail to live up to expectations 90% of time.
 








Saw several resumes come thru, thought it was strange so went and found this thread….now I understand why……I know the company leadership is really bad, esp Covelo and the posse she brought over (have u seen the strategy team? What a joke)….bad company with bad people with no vision will def drive good people away
 








Its not just the medical. Look at the commercial. They have something good with adagrasib. But they decided to bring on a piss poor team based on zero reference checking.

short this while its over a hundred. It will be 70-80 by March-April. By Q4 it will be in the 30's. valuation is bloated like a tick on a elephants A$$
 




Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Simply Wall St News

Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX)


Market forces rained on the parade of Mirati Therapeutics, Inc. (NASDAQ:MRTX) shareholders today, when the analysts downgraded their forecasts for next year. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

After the downgrade, the consensus from Mirati Therapeutics' 13 analysts is for revenues of US$45m in 2022, which would reflect a stressful 38% decline in sales compared to the last year of performance. Losses are supposed to balloon 44% to US$12.64 per share. However, before this estimates update, the consensus had been expecting revenues of US$57m and US$12.31 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts.
 




anonymous said:
Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) - Simply Wall St News

Analyst Forecasts Just Became More Bearish On Mirati Therapeutics, Inc. (NASDAQ:MRTX)


Market forces rained on the parade of Mirati Therapeutics, Inc. (NASDAQ:MRTX) shareholders today, when the analysts downgraded their forecasts for next year. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

After the downgrade, the consensus from Mirati Therapeutics' 13 analysts is for revenues of US$45m in 2022, which would reflect a stressful 38% decline in sales compared to the last year of performance. Losses are supposed to balloon 44% to US$12.64 per share. However, before this estimates update, the consensus had been expecting revenues of US$57m and US$12.31 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts.
Click to expand...

Meek continues to do his magic.
 












FDA reviewing Mirati's lung cancer drug — but taking longer to do it


The FDA is reviewing Mirati's KRAS-blocking lung cancer drug — but taking longer to do it


Mirati Therapeutics said Tuesday that U.S. regulators accepted an application for its KRAS-blocking lung cancer drug, but the review time will be longer than hoped.

The Food and Drug Administration granted a standard review to the Mirati drug called adagrasib, which sets the approval decision date on Dec. 14 — four months later than the company had requested.
 
























STAT: Mirati’s cancer drug isn’t an FDA priority

The FDA accepted Mirati Therapeutics’ application for a novel cancer drug, the company said, but the review time will be longer than it had hoped.

As STAT’s Adam Feuerstein reports, the FDA granted a so-called standard review to Mirati’s drug, adagrasib, which sets the approval decision date on Dec. 14. That’s four months later than the company wanted when it requested a shorter priority review. The FDA declined that request because Amgen’s Lumakras, which uses the same mechanism, is already approved, according to Mirati.

This could set in motion a snowball for Mirati. Amgen is finishing a clinical trial that, if successful, will likely lead the FDA to change Lumakras’ accelerated approval to a full approval. If that happens before adagrasib’s review is complete, the FDA could reject the Mirati drug on the grounds that the Amgen drug satisfies the medical need for similar patients.

Read more.
 




Will be hilarious to watch Meeks ruffle his feathers and wiggle his chin back and forth like a turkey

then a couple of harrumphs

In 2022 our annual sales are zero and it’s all the FDA’s fault. I have Right sized Mirati by firing sufficient people to support my bloated salary. We will inlicense a major oncology development program (as long as I get a bonus) and it will not blow up until immediately after I take severance. Mirati is like deja BOOM … didn’t we see Meeks blow up before ??
 












Top Bottom
Back
Quote